PMID- 25794133
OWN - NLM
STAT- MEDLINE
DCOM- 20150916
LR  - 20181113
IS  - 2044-5385 (Electronic)
IS  - 2044-5385 (Linking)
VI  - 5
IP  - 3
DP  - 2015 Mar 20
TI  - A robust and rapid xenograft model to assess efficacy of chemotherapeutic agents 
      for human acute myeloid leukemia.
PG  - e297
LID - 10.1038/bcj.2015.19 [doi]
AB  - Relevant preclinical mouse models are crucial to screen new therapeutic agents 
      for acute myeloid leukemia (AML). Current in vivo models based on the use of 
      patient samples are not easy to establish and manipulate in the laboratory. Our 
      objective was to develop robust xenograft models of human AML using 
      well-characterized cell lines as a more accessible and faster alternative to 
      those incorporating the use of patient-derived AML cells. Five widely used AML 
      cell lines representing various AML subtypes were transplanted and expanded into 
      highly immunodeficient non-obese diabetic/LtSz-severe combined immunodeficiency 
      IL2Rgammac(null) mice (for example, cell line-derived xenografts). We show here that 
      bone marrow sublethal conditioning with busulfan or irradiation has equal 
      efficiency for the xenotransplantation of AML cell lines. Although higher number 
      of injected AML cells did not change tumor engraftment in bone marrow and spleen, 
      it significantly reduced the overall survival in mice for all tested AML cell 
      lines. On the basis of AML cell characteristics, these models also exhibited a 
      broad range of overall mouse survival, engraftment, tissue infiltration and 
      aggressiveness. Thus, we have established a robust, rapid and straightforward in 
      vivo model based on engraftment behavior of AML cell lines, all vital 
      prerequisites for testing new therapeutic agents in preclinical studies.
FAU - Saland, E
AU  - Saland E
AD  - 1] Cancer Research Center of Toulouse, INSERM, U1037, Toulouse, France [2] 
      University of Toulouse, Toulouse, France.
FAU - Boutzen, H
AU  - Boutzen H
AD  - 1] Cancer Research Center of Toulouse, INSERM, U1037, Toulouse, France [2] 
      University of Toulouse, Toulouse, France.
FAU - Castellano, R
AU  - Castellano R
AD  - 1] Cancer Research Center of Marseille, INSERM, U1068, Marseille, France [2] 
      Institut Paoli-Calmettes, Marseille, France [3] Aix-Marseille Universite, 
      Marseille, France [4] CNRS, UMR7258, Marseille, France.
FAU - Pouyet, L
AU  - Pouyet L
AD  - 1] Cancer Research Center of Marseille, INSERM, U1068, Marseille, France [2] 
      Institut Paoli-Calmettes, Marseille, France [3] Aix-Marseille Universite, 
      Marseille, France [4] CNRS, UMR7258, Marseille, France.
FAU - Griessinger, E
AU  - Griessinger E
AD  - 1] Centre Mediterraneen de Medecine Moleculaire, INSERM, U1065, Nice, France [2] 
      Universite de Nice Sophia Antipolis, Nice, France.
FAU - Larrue, C
AU  - Larrue C
AD  - 1] Cancer Research Center of Toulouse, INSERM, U1037, Toulouse, France [2] 
      University of Toulouse, Toulouse, France.
FAU - de Toni, F
AU  - de Toni F
AD  - 1] Cancer Research Center of Toulouse, INSERM, U1037, Toulouse, France [2] 
      University of Toulouse, Toulouse, France.
FAU - Scotland, S
AU  - Scotland S
AD  - 1] Cancer Research Center of Toulouse, INSERM, U1037, Toulouse, France [2] 
      University of Toulouse, Toulouse, France.
FAU - David, M
AU  - David M
AD  - 1] Cancer Research Center of Toulouse, INSERM, U1037, Toulouse, France [2] 
      University of Toulouse, Toulouse, France.
FAU - Danet-Desnoyers, G
AU  - Danet-Desnoyers G
AD  - Department of Medicine, University of Pennsylvania School of Medicine, 
      Philadelphia, PA, USA.
FAU - Vergez, F
AU  - Vergez F
AD  - 1] Cancer Research Center of Toulouse, INSERM, U1037, Toulouse, France [2] 
      University of Toulouse, Toulouse, France.
FAU - Barreira, Y
AU  - Barreira Y
AD  - Service d'Experimentation Animale, UMS006, 31059, Toulouse cedex, France.
FAU - Collette, Y
AU  - Collette Y
AD  - 1] Cancer Research Center of Marseille, INSERM, U1068, Marseille, France [2] 
      Institut Paoli-Calmettes, Marseille, France [3] Aix-Marseille Universite, 
      Marseille, France [4] CNRS, UMR7258, Marseille, France.
FAU - Recher, C
AU  - Recher C
AD  - 1] Cancer Research Center of Toulouse, INSERM, U1037, Toulouse, France [2] 
      University of Toulouse, Toulouse, France [3] Departement d'Hematologie, Centre 
      Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer Toulouse 
      Oncopole, Toulouse cedex, France.
FAU - Sarry, J-E
AU  - Sarry JE
AD  - 1] Cancer Research Center of Toulouse, INSERM, U1037, Toulouse, France [2] 
      University of Toulouse, Toulouse, France.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150320
PL  - United States
TA  - Blood Cancer J
JT  - Blood cancer journal
JID - 101568469
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*administration & dosage/adverse effects
MH  - Bone Marrow Cells/drug effects
MH  - Cell Line, Tumor
MH  - Humans
MH  - Leukemia, Myeloid, Acute/*drug therapy/genetics/pathology
MH  - Mice
MH  - Xenograft Model Antitumor Assays/*methods
PMC - PMC4382660
EDAT- 2015/03/21 06:00
MHDA- 2015/09/17 06:00
PMCR- 2015/03/01
CRDT- 2015/03/21 06:00
PHST- 2015/01/19 00:00 [received]
PHST- 2015/02/02 00:00 [accepted]
PHST- 2015/03/21 06:00 [entrez]
PHST- 2015/03/21 06:00 [pubmed]
PHST- 2015/09/17 06:00 [medline]
PHST- 2015/03/01 00:00 [pmc-release]
AID - bcj201519 [pii]
AID - 10.1038/bcj.2015.19 [doi]
PST - epublish
SO  - Blood Cancer J. 2015 Mar 20;5(3):e297. doi: 10.1038/bcj.2015.19.